Table 2

RAF1 and FGFR1 alterations and tumor phenotype

RAF1FGFR1
AllAmplifiedPDeletedPAllAmplifiedPDeletedP
Tumor samples successfully analyzeda11944.0%2.2%12213.4%9.9%
Histologyb
 Transitional cell carcinoma2508.0%6.4%2506.0%22.0%
 Squamous cell carcinoma260.0%0.0%2810.7%10.7%
 Small cell carcinoma130.0%15.4%0.21c137.7%0.0%
 Sarcomatoid carcinoma100.0%0.0%90.0%22.2%
 Adenocarcinoma50.0%0.0%425.0%0.0%
Staged
 pTa5320.6%0.0%5501.5%3.5%
 pT12757.3%<0.0001e0.4%2813.2%<0.0001e10.3%<0.0001e
 pT1−4710.6%10.6%<0.0001f466.5%21.7%
 pT2–42508.0%6.4%<0.0001g2506.0%22.0%
Gradec
 G11590.0%0.0%1520.7%0.7%
 G25091.6%<0.0001h0.8%<0.0001h5411.5%<0.0001h5.5%<0.0001h
 G34409.1%4.1%4396.2%18.7%
Growth patternb,c
 Papillary1015.9%3.0%966.3%20.8%
 Solid1468.9%0.3311i8.9%0.0577i1525.9%0.9039i23.0%0.7861i
  • a Only first biopsies.

  • b Only pT2–4.

  • c Small cell versus transitional cell cancer.

  • d Only transitional cell carcinomas.

  • e pTa versus pT1.

  • f pT1 versus pT1−.

  • g pT1 versus pT2–4.

  • h G1 versus G2 versus G3.

  • i Papillary versus solid.